Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Myriad Genetics introduces online prenatal genetic testing resource
Myriad Genetics (MYGN) has launched a new educational website providing comprehensive information about reproductive and prenatal genetic ...
Hosted on MSN1d
NCCN Publishes Vital Patient Resource on Genetic Testing for Hereditary Cancers
The National Comprehensive Cancer Network® (NCCN®) has released a new resource aimed at helping individuals understand genetic testing and counseling for hereditary cancers. This patient-friendly ...
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...